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Abstract
BACKGROUND 
The importance of the neuronal microenvironment has been recently highlighted 
in gut region-specific diabetic enteric neuropathy. Regionally distinct thickening 
of endothelial basement membrane (BM) of intestinal capillaries supplying the 
myenteric ganglia coincide with neuronal damage in different intestinal segments. 
Accelerated synthesis of matrix molecules and reduced degradation of matrix 
components may also contribute to the imbalance of extracellular matrix 
dynamics resulting in BM thickening. Among the matrix degrading proteinases, 
matrix metalloproteinase 9 (MMP9) and its tissue inhibitor (TIMP1) are essential 
in regulating extracellular matrix remodelling.
AIM 
To evaluate the intestinal segment-specific effects of diabetes and insulin 
replacement on ganglionic BM thickness, MMP9 and TIMP1 expression.
METHODS 
Ten weeks after the onset of hyperglycaemia gut segments were taken from the 
duodenum and ileum of streptozotocin-induced diabetic, insulin-treated diabetic 
and sex- and age-matched control rats. The thickness of BM surrounding 
myenteric ganglia was measured by electron microscopic morphometry. Whole-
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mount preparations of myenteric plexus were prepared from the different gut 
regions for MMP9/TIMP1 double-labelling fluorescent immunohistochemistry. 
Post-embedding immunogold electron microscopy was applied on ultrathin 
sections to evaluate the MMP9 and TIMP1 expression in myenteric ganglia and 
their microenvironment from different gut segments and conditions. The MMP9 
and TIMP1 messenger ribonucleic acid (mRNA) level was measured by 
quantitative polymerase chain reaction.
RESULTS 
Ten weeks after the onset of hyperglycaemia, the ganglionic BM was significantly 
thickened in the diabetic ileum, while it remained intact in the duodenum. The 
immediate insulin treatment prevented the diabetes-related thickening of the BM 
surrounding the ileal myenteric ganglia. Quantification of particle density showed 
an increasing tendency for MMP9 and a decreasing tendency for TIMP1 from the 
proximal to the distal small intestine under control conditions. In the diabetic 
ileum, the number of MMP9-indicating gold particles decreased in myenteric 
ganglia, endothelial cells of capillaries and intestinal smooth muscle cells, 
however, it remained unchanged in all duodenal compartments. The 
MMP9/TIMP1 ratio was also decreased in ileal ganglia only. However, a marked 
segment-specific induction was revealed in MMP9 and TIMP1 at the mRNA 
levels.
CONCLUSION 
These findings support that the regional decrease in MMP9 expression in 
myenteric ganglia and their microenvironment may contribute to extracellular 
matrix accumulation, resulting in a region-specific thickening of ganglionic BM.
Key Words: Type 1 diabetes; Diabetic enteric neuropathy; Neuronal microenvironment; 
Basement membrane; Matrix metalloproteinase 9; Tissue inhibitor of metalloproteinase 1
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: These findings demonstrate an intestinal segment-specific thickening of 
basement membrane (BM) surrounding myenteric ganglia. In diabetes, ganglionic BM 
is thickened in the ileum, but not in the duodenum. Insulin prevented the diabetes-
related BM thickening. The matrix degrading matrix metalloproteinase 9 (MMP9) 
expression was decreased in myenteric ganglia and its environment in the diabetic 
ileum, however, it remained unchanged in the duodenum. Similarly, MMP9/Tissue 
inhibitor of metalloproteinase 1 (TIMP1) ratio decreased only in ileal myenteric 
ganglia. Intestinal segment-specific induction of MMP9 and TIMP1 messenger 
ribonucleic acid levels was revealed. Regionally decreased MMP9 expression in 
ganglia correlates well with segment-specific thickening of ganglionic BM and these 
coincide with region-dependent enteric neuronal damage.
Citation: Bódi N, Mezei D, Chakraborty P, Szalai Z, Barta BP, Balázs J, Rázga Z, Hermesz E, 
Bagyánszki M. Diabetes-related intestinal region-specific thickening of ganglionic basement 
membrane and regionally decreased matrix metalloproteinase 9 expression in myenteric 




In the last few years, there has been an increasing emphasis on the importance of the 
neural microenvironment in the diabetic damage of the enteric nervous system[1-3]. 
Moreover, the region-specific susceptibility of enteric neurons to diabetic neuropathy 
and their sensibility to immediate insulin treatment[4,5] serve as further motivation to 
thoroughly investigate the molecular neural milieu in different intestinal segments.
Bódi N et al. Enteric ganglionic basement membrane and MMP9
WJD https://www.wjgnet.com 660 May 15, 2021 Volume 12 Issue 5
Country/Territory of origin: 
Hungary
Peer-review report’s scientific 
quality classification
Grade A (Excellent): 0 
Grade B (Very good): B 
Grade C (Good): 0 
Grade D (Fair): 0 
Grade E (Poor): 0
Received: February 2, 2021 
Peer-review started: February 2, 
2021 
First decision: February 27, 2021 
Revised: March 10, 2021 
Accepted: April 21, 2021 
Article in press: April 21, 2021 
Published online: May 15, 2021
P-Reviewer: Slomiany BL 
S-Editor: Zhang L 
L-Editor: A 
P-Editor: Ma YJ
Since enteric ganglia are not vascularized, the capillaries in close vicinity have a 
critical role to supply them with oxygen and nutrients[6]. It is well established that 
among others, the thickened endothelial basement membrane (BM) is one of the 
earliest histological hallmarks of diabetic microangiopathy contributing to impaired 
permeability function in retina or renal glomeruli[7-11]. Consistent with this, we 
revealed a strictly intestinal region-dependent thickening and separation of capillary 
BM in type 1 diabetic rat model[12]. Structural and morphological findings (e.g., 
opened endothelial tight junctions, enlarged caveolar compartments, impaired distri-
bution of endogenous albumin) suggesting altered permeability of intestinal 
capillaries in the vicinity of myenteric ganglia were also revealed[12].
There may be several reasons for capillary BM thickening. On the one hand, the 
diabetes-related enhanced expression of the prevalent BM components leads to 
thickened BM. High glucose-induced overexpression of collagen IV, fibronectin, 
laminin, agrin and tenascin was observed in different models[10,13-16]. On the other 
hand, due to the long-lasting hyperglycaemic condition, the decreased degradation of 
these BM components may also result in a thickened BM, even under good glycaemic 
control. In rats with diabetic nephropathy, the decreased metalloproteinase activity 
promotes the accumulation of collagen IV in the matrix[17]. Others also observed an 
accelerated matrix accumulation in metalloproteinase knockout mice[18]. Overall, the 
accumulation of extracellular matrix (ECM) molecules and/or the decreased 
degradation of matrix components may contribute to the imbalance in ECM dynamics 
and lead to BM thickening.
ECM proteins are degraded by several proteinases[19]. Among them, metallopro-
teinases are the most essential in regulating ECM remodelling[19]. Matrix metallopro-
teinases (MMPs) are calcium-dependent zinc-containing endopeptidases[20]. The 
MMP family has more than 20 members in vertebrates, most of them with basic three-
domain structures and different ECM and other targets[21]. However, MMPs have not 
only proteinase activity, but are also implicated in other essential functions, like 
releasing apoptotic ligands, cytokine inactivation, cell proliferation and differentiation, 
angiogenesis, and host defense[19,21-23].
MMP9 is secreted by a wide variety of cells, such as macrophages, smooth muscle 
cells, endothelial cells, and it is one of the most extensively studied enzymes involved 
in ECM breakdown and turnover. Due to the crosstalk between ECM and inflamma-
tory processes, MMPs are associated with the development of diabetic microvascular 
complications in different organs[24]. MMP activation accelerates apoptotic processes 
in retina[25]. There is correlation also between upregulated MMP expression and the 
progression of diabetic nephropathy[26,27]. Under diabetic conditions, MMP 
expression is influenced by high glucose level and reactive oxygen species[27]. 
Moreover, the endogenous tissue inhibitors of metalloproteinases (TIMPs), are crucial 
to determine the optimal proteolytic activity of MMPs[28]. Among the four members 
of TIMP family, TIMP1 has the strongest efficiency to inhibit most of the MMPs[29]. 
TIMPs can directly restrict MMP-dependent matrix proteolysis or indirectly facilitate 
ECM accumu-lation[29].
All enteric ganglia are surrounded with a continuous BM[6,30], and the components 
of this ECM sheet are not detectable inside the enteric ganglia[31]. Several studies 
dealt with the composition and alterations of ECM in the intestinal wall due to its 
impact on enteric ganglion formation during development[32-34]. The appropriate 
matrix composi-tion is indispensable for the development of enteric ganglia and 
normal nerve fibre function[33,35]. The relevance of different BM abnormalities was 
investigated in Hirschprung’s disease[36-38], however, little is known about its role in 
other pathological processes, like diabetes-related enteric neuropathy.
We assume that structural and molecular alterations involved in maintaining the 
dynamic structure of ECM in the intestinal wall may contribute to the gut region-
dependent diabetic neuropathy. Therefore, the primary goal of this study was to 
evaluate the effects of type 1 diabetes and immediate insulin replacement on BM 
thickness surrounding myenteric ganglia in different gut segments. Furthermore, we 
aimed to investigate the intestinal region-dependent expression of MMP9 and TIMP1 




Adult male Wistar rats (Crl: WI BR; Toxi-Coop Zrt.) kept on standard laboratory chow 
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(Farmer-Mix Kft., Hungary) and with free access to drinking water, were used 
throughout the experiments. The rats, weighing 200-300 g, were divided randomly 
into three groups: streptozotocin (STZ)-induced diabetics (n = 4), STZ-induced 
diabetics with insulin treatment (n = 4) and sex- and age-matched controls (n = 4). The 
controls were treated with vehicle, while hyperglycaemia was induced by a single 
intraperitoneal injection of STZ (Sigma-Aldrich, Hungary) at 60 mg/kg as described 
previously[4,12]. The animals were considered diabetic if the non-fasting blood 
glucose concentration was higher than 18 mmol/L. From this time on, the insulin-
treated hyperglycaemic group received a subcutaneous injection of insulin (Humulin 
M3; Eli Lilly Nederland, Netherlands) each morning (2 IU) and afternoon (2 IU). 
Equivalent volumes of saline were given subcutaneously to the rats in the diabetic and 
the control group. The blood glucose level and weight of each animal were measured 
weekly during the 10-wk experimental period. Those STZ-induced diabetic animals 
which recover spontaneously or their blood glucose level decreased under 18 mmol/L 
during the 10-wk experimental period did not participate in this study.
The animal protocol was designed to minimize pain or discomfort to the animals. 
The animals were acclimatized to laboratory conditions (23 °C, 12 h/12 h light/dark, 
50% humidity, ad libitum access to food and water) for 2 wk prior to experimentation.
In all procedures involving experimental animals, the principles of the National 
Institutes of Health (Bethesda, MD, United States) guidelines and the EU directive 
2010/63/EU for the protection of animals used for scientific purposes were strictly 
followed, and all the experiments were approved by the National Scientific Ethical 
Committee on Animal Experimentation (National Competent Authority), with the 
license number XX./1636/2019.
Tissue handling
Ten weeks after the onset of hyperglycaemia, the animals were euthanized by 
barbiturate overdose (150 mg/kg pentobarbital sodium i.v. injection) for tissue 
collection. The gut segments of the control, STZ-induced diabetic, and insulin-treated 
diabetic rats were dissected and rinsed in 0.05 mol/L phosphate buffer (PB; pH 7.4). 
Samples were taken from the duodenum (1 cm distal to the pylorus) and the ileum (1 
cm proximal to the ileo–caecal junction), and processed for fluorescent immunohisto-
chemistry, quantitative electron microscopy and quantitative polimerase chain 
reaction (qPCR). For double-labelling fluorescent immunohistochemistry, samples (2-3 
mm) from different gut segments were fixed in 4% paraformaldehyde (PFA) and 
embedded in melted paraffin. For electron microscopic studies, small pieces (2-3 mm) 
of the gut segments were fixed in 2% PFA and 2% glutaraldehyde solution and then 
further fixed for 1 h in 1% OsO4. After rinsing in buffer and dehydrating in increasing 
ethanol concentrations and acetone, they were embedded in Embed812 (Electron 
Microscopy Sciences, United States). The Embed blocks were used to prepare ultrathin 
(70 nm) sections, which were mounted on nickel grids and processed for morpho-
metrical study and immunogold labelling. For qPCR study, the 3-cm-long gut 
segments were cut along the mesentery and pinched flat. The layer of mucosa and 
submucosa was removed, and the residual material (myenteric plexus and intestinal 
smooth muscle layers) was snap-frozen in liquid nitrogen and stored at -80 °C until 
use.
Double-labelling fluorescent immunohistochemistry
For double-labelling immunohistochemistry, paraffin-sections (3.5 µm) derived from 
different gut segments were immunostained with MMP9 and TIMP1. Briefly, after 
blocking in TRIS-buffered saline (TBS) containing 1% bovine serum albumin and 10% 
normal goat serum, the sections were incubated overnight with anti-MMP9 (mouse 
monoclonal immunoglobulin G (IgG); Abcam, UK; final dilution 1:100) and anti-
TIMP1 (rabbit polyclonal IgG; Santa Cruz Biotechnology, United States; final dilution 
1:50) primary antibodies at 4 °C. After washing in TBS with 0.025% Triton X-100, 
sections were incubated with anti-mouse CyTM3 (Jackson ImmunoResearch 
Laboratories, Inc., United States; final dilution 1:200) and anti-rabbit Alexa Fluor 488 
(Life Technologies Corporation, Molecular Probes, Inc., United States; final dilution 
1:200) secondary antibodies for 1 h at room temperature. Negative controls were 
performed by omitting the primary antibody when no immunoreactivity was 
observed. Sections were mounted on slides in FluoromountTM Aqueous Mounting 
Medium (Sigma-Aldrich, Hungary), observed and photographed with a Zeiss Imager 
Z.2 fluorescent microscope equipped with an Axiocam 506 mono camera.
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Transmission electron microscopy
Morphometric study: For ultrathin sectioning, four Embed blocks were used for each 
intestinal segment and each condition (control, STZ-induced diabetics, and insulin-
treated diabetics). Three grids per block were counterstained with uranyl acetate 
(Merck, Germany) and lead citrate (Merck, Germany) and were examined and 
photographed with a JEOL JEM 1400 transmission electron microscope. Montage 
photographs of twelve myenteric ganglia per intestinal segment per condition were 
made at a magnification of 20000 × and the thickness of the BM were measured at 
random points around the ganglia with the help of a limited size (700 nm × 700 nm) 
grid net. The mean thickness was then calculated for each ganglion by using the 
AnalySIS 3.2 program (Soft Imaging System GmbH, Germany).
Post-embedding immunohistochemistry
The Embed blocks used previously for the electron microscopic morphometry also 
served for the MMP9 and TIMP1 post-embedding immunohistochemistry. Ultrathin 
sections from each block were sequentially incubated overnight in anti-MMP9 mouse 
monoclonal IgG (Abcam, United Kingdom; final dilution 1:50) or anti-TIMP1 rabbit 
polyclonal IgG (Santa Cruz Biotechnology, United States; final dilution 1:50) primary 
antibodies, followed by colloidal gold conjugated anti-mouse IgG (conjugated to 18 
nm colloidal gold; Jackson Immunoresearch, United States; final dilution 1:20) or anti-
rabbit IgG (conjugated to 18 nm colloidal gold; Jackson Immunoresearch, United 
States; final dilution 1:20) secondary antibodies for 3 h, with extensive TBS washing in-
between. The specificity of the immunoreaction was assessed in all cases by omitting 
the primary antibodies in the labelling protocol and incubating the sections only in the 
gold conjugated secondary antibodies. Sections were counterstained with uranyl 
acetate (Merck, Germany) and lead citrate (Merck, Germany) and were examined and 
photographed with a JEOL JEM 1400 transmission electron microscope. The 
quantitative properties of gold particles coding for MMP9 or TIMP1 were determined 
in the myenteric ganglia, the endothelium of capillaries in the vicinity of these ganglia 
and the intestinal smooth muscle cells. Counting was performed on digital 
photographs at a magnification of 20000 × with the AnalySIS 3.2 program (Soft 
Imaging System GmbH, Germany). Montage pictures of twelve ganglia, the entire 
endothelial profile of eleven well-oriented capillaries and eleven field of view of the 
surrounding smooth muscle cells per intestinal segment per condition were used. The 
intensity of the labelling was expressed as the total number of gold particles per unit 
area.
RNA preparation, reverse transcription and qPCR
Intestinal tissue samples were homogenized in RNA Bee reagent (Tel-Test Inc., United 
States) and total RNA was prepared according to the procedure suggested by the 
manufacturer. For assessing RNA concentration and purity, the absorbance of RNA 
samples was measured at 260 and 280 nm using NanoDrop 1000 UV/VIS Spectropho-
tometer (Thermo Scientific, United States). The RNA concentration was calculated 
using the A260 = 1.0 equivalent to approximately 40 g/mL single-stranded RNA 
equation. The A260/A280 ratio approximately 1.9 was accepted for clean RNA. First-
strand cDNA was synthesized by using 2.5 µg total RNA as template, 200 pmol of each 
dNTP (Thermo Scientific, United States), 200 U Maxima H Minus Reverse 
Transcriptase (Thermo Scientific, United States) and 500 pmol random hexamer 
primers (Sigma-Aldrich, Hungary) in a final volume of 20 µL, and incubated for 10 
min at 37 °C, followed by 45 min at 52 °C. Real-time qPCR was performed for gene 
expression studies, using Luminaris Color HiGreen Low ROX qPCR Master Mix 
(Thermo Scientific, United States) in Applied Biosystems 7500 Real-Time PCR System 
(Life Technologies, Hungary). The qPCR reactions were carried out with a temperature 
program of 10 min at 95 °C (initial denaturing), followed by 45 cycles of 15 s at 95 °C; 
30 s at the annealing temperature 63 °C followed by a melting curve stage with 
temperature ramping from 60 to 95 °C and a final cooling for 30 s at 40 °C. The 
quantities of examined messenger ribonucleic acid (mRNAs) were normalized to that 
of 18 S ribosomal RNA, and gene expression was calculated in terms of 2ΔΔCt 
method[39].
Primers
Primers were designed based on the data bank entries. For normalization of the 
amounts of MMP9 and TIMP1 mRNA, the 18 S RNA level was used as internal 
standard. MMP9 2F: 5’ CTCTACACGGAGCACGGCAACG 3’; MMP9 2R: 5’ 
CGGTGGTGGCGCACCAGCG 3’.TIMP1 2F: 5’ ACAGGTTTCCGGTTCGCCTAC 3’; 
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TIMP1 2R: 5’ CTGCAGGCAGTGATGTGCAA 3’. 18S F: 5’ GAAACGGCTACC 
ACATCCAAGG 3’; 18S R: 5’ CCGCTCCCAAGATCCAACTACG 3’.
Statistical analysis
Statistical analysis was performed with Kruskal-Wallis test, and Dunn’s multiple 
comparisons test (electron microscopic study), or one-way analysis of variance with 
Newman-Keuls test (Table 1 and qPCR study). Statistical analysis of RT-qPCR 
reactions for each animal were performed in triplicate to increase the reliability of the 
measurements. All analyses were carried out with GraphPad Prism (GraphPad 
Software, United States). A probability of P < 0.05 was set as the level of significance.
RESULTS
Disease characteristics of diabetic and insulin-treated diabetic rats
The general characteristics of the STZ-induced diabetic and insulin-treated diabetic, as 
well as the control animals are shown in Table 1. Untreated diabetic rats were charac-
terized by a significantly reduced body weight and a markedly increased blood 
glucose concentration (26.23 ± 1.89 mmol/L) as compared to the sex-and age-matched 
controls (5.99 ± 0.19 mmol/L). In the immediate insulin replacement group, the body 
weight of the animals was similar to controls by the end of the experiment. The blood 
glucose concentration of insulin-treated rats (7.13 ± 1.37 mmol/L) remained at the 
control level during the 10 wk experimental period.
Morphometry of the BM surrounding myenteric ganglia
Myenteric ganglia are surrounded by a thin BM, which delimits the ganglia from the 
adjacent tissues. The collagen fibrils located in the extracellular space never enter into 
the ganglia (Figure 1A).
In controls, BM thickness was the same in the proximal and distal part of the small 
intestine (approximately 34-36 nm), however, a region-specific thickening was 
revealed in diabetic rats. The ganglionic BM was significantly thicker in the diabetic 
ileum relative to control values (44.04 ± 1.62 nm vs 34.85 ± 1.11 nm, P < 0.0001), 
whereas in the duodenum it did not exceed that of the controls (Figure 1B). Although 
the diabetes-related BM thickening was prevented by immediate insulin treatment in 
the ileum, the BM was significantly thinner (26.98 ± 0.93 nm) in this region in insulin-
treated rats (Figure 1B).
Presence of MMP9 and TIMP1 immunoreactivity in the gut wall
Double-labelling fluorescent microscopy revealed MMP9 and TIMP1 immunore-
activity in myenteric ganglia and their environment (Figure 2). The intensity of the 
fluorescent labelling varied among different structures of the gut wall: it was the 
lowest in the ganglia, higher in the intestinal blood vessels, and pronouncedly intense 
in the circular and longitudinal smooth muscle layers (Figure 2).
Quantitative changes in MMP9 expression in different cellular compartments
The expression of MMP9 was further demonstrated by gold-labelling immunoelectron 
microscopy in myenteric ganglia, endothelial cells of capillaries in the vicinity of these 
ganglia and smooth muscle cells (Figure 3). The 18 nm gold particles indicating MMP9 
were often detected in cytosol, nuclei, intracellular organelles of the neuronal 
perikaryon (Figure 3A) and neuropil region (Figure 3B) of the ganglia, caveolar 
compartments, and plasma membrane of endothelial and smooth muscle cells 
(Figure 3C).
In control animals, the density of MMP9-labeling gold particles was significantly 
higher in the myenteric ganglia of the ileum than in the duodenal segment (P < 0.001; 
Figure 4A). Also, higher ileal density of MMP9 particles was observed in endothelial 
and smooth muscle cells (data not shown separately, but visible on Figure 5B and C).
In diabetic rats, the number of MMP9-labeling gold particles significantly decreased 
in the myenteric ganglia (Figure 5A), capillary endothelium (Figure 5B) and intestinal 
smooth muscle (Figure 5C) of the ileum. The greatest decrease has been observed in 
the endothelial cells of diabetics, where the number of MMP9 particles was more than 
half of the controls (0.75 ± 0.11 vs 1.66 ± 0.26). The immediate insulin treatment only 
partially prevented the diabetes-related alterations in MMP9 expression. However, in 
the diabetic duodenum, the number of MMP9 gold particles did not change in the 
myenteric ganglia or in the other cell types in either of the experimental groups 
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Table 1 Weight and glycaemic characteristics of the experimental groups
Weight (g) Blood glucose level (mmol/L)
Initial Final Initial Final (average)
Controls (n = 4) 266 ± 18.85 460.25 ± 22.34b 6.48 ± 0.2 5.99 ± 0.19
Diabetics (n = 4) 274 ± 17.11 382.5 ± 17.69a,c 6.4 ± 0.24 26.23 ± 1.89b,d
Insulin-treated diabetics (n = 4) 274 ± 15.36 457.25 ± 29.33b,e 6.28 ± 0.09 7.13 ± 1.37f
aP < 0.01.
bP < 0.0001 vs initial.
cP < 0.05.
dP < 0.0001 vs final controls.
eP < 0.05.
fP < 0.0001 vs final diabetics. Data are expressed as mean ± SEM.
Figure 1 Representative electron micrograph of a myenteric ganglion from an insulin-treated diabetic rat. A: The myenteric ganglion is 
surrounded by basement membrane (BM) (arrows). Scale bar: 500 nm; B: Quantitative evaluation of BM thickness in different gut segments of control, diabetic, and 
insulin-treated diabetic rats. The thickening of BM surrounding myenteric ganglia remained unchanged in the duodenum, however it increased significantly in the 
ileum of diabetic rats. Immediate insulin treatment prevented BM thickening in the ileum. aP < 0.0001 (relative to the controls); bP < 0.0001 (between diabetics and 
insulin-treated diabetics).
Figure 2 Representative fluorescent micrograph of a paraffin section of myenteric ganglia from the ileum of a control rat after matrix 
metalloproteinase 9-tissue inhibitor of metalloproteinase 1 double-labelling immunohistochemistry. A: Matrix metalloproteinase 9 
immunoreactivity is indicated in red; B: tissue inhibitor of metalloproteinase 1 immunoreactivity is shown in green; and C: The merge is depicted on. Scale bar: 20 μm. 
MG: Myenteric ganglia; LSM: Longitudinal smooth muscle layer; CSM: Circular smooth muscle layer; arrows-blood vessels.
(Figure 5).
Quantitative changes in TIMP1 expression and MMP9/TIMP1 ratio
TIMP1 displayed a quite low, but region-dependent expression in the myenteric 
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Figure 3 Representative electron micrographs subjected to matrix metalloproteinase 9 post-embedding immunohistochemistry. A: 
Myenteric ganglia from a control duodenum; B: A diabetic ileum; and C: Capillary endothelium and intestinal smooth muscle from a control duodenum. The 18 nm 
gold particles (arrows) indicating matrix metalloproteinase 9 were observed in cytosol, nuclei or in association with intracellular organelles and plasma membrane. 
Scale bars: 500 nm. P: Neuronal perikaryon; N: Nucleus; SMC: Smooth muscle cell; EC: Endothelial cell; LU: Capillary lumen.
Figure 4 Quantitative changes in MMP9 and TIMP1 expression. A: Quantitative evaluation of matrix metalloproteinase 9 (MMP9); and B: Quantitative 
evaluation of tissue inhibitor of metalloproteinase 1 (TIMP1) labelling gold particles in myenteric ganglia from different gut segments of control rats. In control 
conditions, the number of MMP9 particles was significantly higher, while TIMP1-labeling was significantly lower in the distal part of the small intestine. Data are 
expressed as means ± SEM. aP < 0.01 and bP < 0.001 (between control duodenum and control ileum).
ganglia of different gut segments in control conditions. The number of TIMP1-labeling 
gold particles was half in the ileal than in the duodenal ganglia (P < 0.01; Figure 4B). 
There were no significant differences in the distribution of TIMP1 gold particles 
between different intestinal regions in other control cell types (data not shown). In 
addition, neither the hyperglycaemia nor the immediate insulin treatment resulted in 
any significant alterations in the number of TIMP1-labeling gold particles in either of 
the cellular compartments (data not shown).
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Figure 5 Quantitative changes in matrix metalloproteinase 9 expression in different cellular compartments. A: Quantitative evaluation of matrix 
metalloproteinase 9 (MMP9)-labeling gold particles in myenteric ganglia; B: Capillary endothelium; and C: Intestinal smooth muscle cells from different gut segments 
of control, diabetic, and insulin-treated diabetic rats. In diabetics, the number of MMP9-labeling gold particles was significantly decreased in all cellular compartments 
of the ileum, while it was unchanged in the duodenum relative to controls. The number of gold particles was closer to the control values after immediate insulin 
treatment. Data are expressed as means ± SEM. aP < 0.05 and bP < 0.01 (relative to controls).
However, a region-specific MMP9/TIMP1 ratio was observed in the myenteric 
ganglia. While the MMP9/TIMP1 ratio remained unchanged in the duodenum, the 
decrease in the ratio was nearly 50% in the ileal ganglia of diabetic rats (Figure 6). The 
MMP9/TIMP1 ratio was more than double in the duodenum, while it was close to the 
control value in the ileum in the insulin-treated group (Figure 6).
Quantitative alterations in mmp9 and timp1 mRNA expression
The expression level of MMP9 mRNA markedly increased in both gut segments under 
chronic hyperglycaemic conditions. The rate of induction was approximately 5.5-fold 
in tissue homogenates prepared from the diabetic duodenum, and approximately 7.0-
fold in the diabetic ileum relative to controls and normalized to the endogenous 18S 
RNA as reference (Figure 7).
In parallel, TIMP1 mRNA expression was highly upregulated (approximately 5-
fold) in tissue homogenates originating from the ileum, while it remained unchanged 
in duodenal homogenates of diabetic rats (Figure 7).
DISCUSSION
In accordance with our principle findings that diabetic myenteric neuropathy is 
intestinal region-dependent[4], and that the neuronal microenvironment is also 
suffering from a series of strictly region-specific diabetic damages[12,40], the present 
study provides more evidence of gut segment-specific, diabetes-related alterations of 
the ECM biology in myenteric ganglia, intestinal capillaries and smooth muscle of the 
gut wall.
We have shown for the first time that the BM surrounding myenteric ganglia is 
regionally thickened along the small intestine. The thickness was increased by more 
than 25% in the ileum, while it was unchanged in the duodenum of diabetic rats. 
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Figure 6 The ratio of matrix metalloproteinase 9 and tissue inhibitor-labeling gold particles in myenteric ganglia of different gut segments 
of control, diabetic, and insulin-treated diabetic rats. In diabetic rats, the matrix metalloproteinase 9/tissue inhibitor of metalloproteinase 1 ratio was not 
altered in duodenal, but was markedly decreased in ileal ganglia. The immediate insulin replacement did not restore the equilibrium ratio observed in controls.
Figure 7 Fold change in the messenger ribonucleic acid levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 
genes, measured by real-time fluorescence-based quantitative polymerase chain reaction using the 2ΔΔCt method. Data sets are presented as 
the fold change in gene expression normalized to the endogenous reference (RNA18S) and relative to the untreated controls. Data are expressed as means ± 
standard deviation. aP < 0.001 and bP < 0.0001.
Using the same type 1 diabetic rat model, we formerly demonstrated that the 
endothelial BM of intestinal capillaries supplying the enteric ganglia displayed similar 
structural alterations[12]. The thickening and separation of capillary BM was 
pronounced in the distal part of the gastrointestinal tract, but not in the duodenum of 
diabetics[12], which suggests optimal and very stable conditions in the duodenum 
while a more susceptible microenvironment is plausible in the ileum along the 
proximal-distal axis of the gut. Other findings include increased amount of ECM 
proteins (laminin-1 and fibronectin), as well as BM thickening of the small intestinal 
smooth muscle cells in diabetic rats[41], and also significant thickening of perineurial 
cell BM and loss of myelinated nerve fibres in diabetic peripheral neuropathies[42-44]. 
The immediate insulin replacement prevented diabetes-related BM thickening 
surrounding the ileal myenteric ganglia, as it inhibited the BM thickening of capillary 
endothelium[12] or reversed the hyperglycaemia-induced ECM accumulation in the 
intestinal smooth muscle layers[41]. Among the underlying mechanisms of ECM 
accumulation resulting in both ganglionic and endothelial BM thickening, the matrix 
degrading metalloproteinases have become the focus of the present study. We have 
shown that MMP9 and TIMP1 is present in myenteric ganglia and their environment 
using fluorescent and electron microscopy. The ultrastructural localization of these 
markers within the cytoplasm and nuclei of the enteric neurons, endothelial and 
smooth muscle cells was in agreement with other findings[45,46]. The nuclear 
localization of MMPs may have a role in regulation the activity of DNA-repairing and 
apoptotic proteins[47,48].
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Quantitative immunogold labelling showed that the MMP9 particle density 
increased, while the TIMP1 particle density decreased in myenteric ganglia along the 
proximal-distal axis of the small intestine under control conditions. In addition to this 
opposite tendency, we observed that the particle density of TIMP1 was an order of 
magnitude lower than that of MMP9. In diabetic rats, the MMP9-indicating gold 
particles decreased in all cell types of the ileum, however, they remained unchanged in 
all duodenal compartments. Moreover, the MMP9/TIMP1 ratio was also decreased 
only in the ileal ganglia, but not in the duodenum. Immediate insulin replacement 
prevented diabetic alterations only in part as it was described in other studies[4,5,12].
The region-dependent BM thickening and changes in MMP production in different 
cellular compartments correlate well with each other. In the diabetic ileum, the 
decrease in MMP9 expression both in myenteric ganglia, and endothelial and smooth 
muscle cells suggests a decreased breakdown of ECM components resulting in ECM 
accumulation and thickening of BM around the myenteric ganglia and also the 
intestinal capillaries[12]. However, in the diabetic duodenum, where MMP9 
production remained optimal in all cell types, the thickness of ganglionic and 
endothelial BM also remained unchanged[12].
Although we did not observe significant changes in the distribution of TIMP1 
protein-detecting gold particles in different cell types under diabetic conditions and 
after insulin treatment, the segment-specific induction of both MMP9 and TIMP1 
mRNA expression was demonstrated. Meanwhile, the MMP9 induction was not 
accompanied by altered TIMP1 expression in the duodenal tissue homogenates of 
diabetics, however, in the ileal samples, a 7-fold increase in MMP9 mRNA level was 
detected, along with a great upregulation in TIMP1 mRNA expression. The regulation 
of MMPs/TIMPs expression and activity is complex, involving both transcriptional 
and post-transcriptional mechanisms using multiple signal pathways, microRNA 
modulation, post-translational modifications and extracellular inhibition[21,49-51]. 
Based on these findings, we presume that despite of the MMP9 transcriptional 
alterations, due to post-transcriptional modifications[49], the balance in the production 
of MMP9 and TIMP1 proteins was retained in the duodenum, which contributes to the 
maintenance of optimal ECM dynamics in this segment. In contrast, in the ileum, not 
only MMP9 but also TIMP1 transcription was highly upregulated, resulting in MMP9 
protein underproduction and ECM accumulation. Inconsistent alterations of MMP9 
mRNA and protein expression presuming post-transcriptional regulation were also 
observed in diabetic nephropathy[52]. Moreover, upregulated microRNA production 
resulted in decreased MMP9 expression, which in turn contributed to renal fibrosis in 
diabetic kidney[52,53]. Decreased matrix degradation due to increased MMP mRNA 
level, but decreased activity was also documented in diabetic nephropathy[17,54], 
modulated by advanced glycation end products[55]. Increased fibrosis was also 
demonstrated in MMP knockout mice[18]. In contrast, some studies report that MMP 
overexpression promotes renal fibrosis due to a possible interplay with TIMPs[51,56], 
while others revealed that MMP2 and MMP9 triggered mitochondrial damage and 
apoptotic processes in retinal capillaries[57-59].
However, it certainly seems that the imbalance in MMP/TIMP ratio[60,61] caused 
by various molecular mechanisms disturbs the equilibrium of ECM degradation and 
turnover and contributes to several inflammatory processes, as well as vascular or 
neuronal damage, which requires further investigations.
CONCLUSION
Overall, in the present study, we provided evidence that the region-dependent 
thickening of ganglionic basement membrane is closely related to the regionally 
decreased MMP9 expression in myenteric ganglia and its environment, coinciding 
with the intestinal region-specific enteric neuropathy in type 1 diabetes.
ARTICLE HIGHLIGHTS
Research background
The diabetic damage of enteric neurons and intestinal capillaries supplying the enteric 
ganglia are strictly intestinal region dependent. Therefore, the underlying molecular 
differences in the neuronal environment should be more emphasized.
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Research motivation
To prove the presence of essential regional differences in the neuronal milieu which 
may explain the gut segment-specific enteric neuropathy and vascular dysfunction.
Research objectives
To reveal the impact of diabetes and immediate insulin treatment on the thickness of 
basement membrane (BM) surrounding myenteric ganglia, as well as the expression of 
matrix metalloproteinase 9 (MMP9) and its tissue inhibitor of metalloproteinase 1 
(TIMP1) which are key players in regulating extracellular matrix dynamics.
Research methods
Electron microscopic morphometry, fluorescent and gold-labelling immunohisto-
chemistry and quantitative polymerase chain reaction were applied to study the 
myenteric ganglia and their environment in the different gut segments of diabetic, 
insulin-treated diabetic and control rats.
Research results
In the diabetic ileum, the ganglionic BM was significantly thickened which was 
prevented by insulin treatment. These changes were also reflected in a decrease in 
MMP9/TIMP1 ratio in ileal myenteric ganglia. However, in the duodenum of diabetics 
neither the ganglionic BM thickness nor the MMP9/TIMP1 ratio were changed.
Research conclusions
Regionally decreased MMP9 expression in ganglia and region-dependent ganglionic 
BM thickening correlate well with intestinal segment-specific enteric neuropathy.
Research perspectives
Based on these findings in type 1 diabetic rat model, we are planning to expand our 
investigations to type 2 diabetes in the future.
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